B+
Bull case
25%
Probability
Target price
$1.10
Analysis reference price unavailable
Analysis 2026-08-28 · RankAlpha Sentiment Codex
CALC
CalciMedicaFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The financing and FDA-aligned acute-pancreatitis design give CalciMedica a more defined clinical roadmap than the prior monitoring view. Mid-2027 PAH data and the CM5480 IND could materially improve sentiment if execution and early clinical evidence are favorable.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Additional financing, dilution, or capital-structure actions may be required despite the recent private placement.
Momentum
99
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.45 · Bull $1.10 · Bear $0.18Analysis 2026-08-28; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-28 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $37.50
Why
Momentum99 · Δ7d -
Value41 · Δ7d -0.0
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Additional financing, dilution, or capital-structure actions may be required despite the recent private placement.
- • Phase 1b PAH data and the CM5480 IND are not expected until mid-2027, leaving limited near-term fundamental visibility.
- • CalciMedica remains a clinical-stage biotech without commercial revenue, with a reported Q2 loss worse than analyst expectations and substantial dependence on future financing, trial execution, regulatory progress, and eventual clinical efficacy.
Catalyst clock
2026-11-26
Pulmonary hypertension clinical and regulatory milestones
Lead driver: Value · See fundamentals
Momentum
99
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
0
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 99.0 / Value 41.2 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-28. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$0.45
Analysis reference price unavailable
Analysis 2026-08-28 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$0.18
Analysis reference price unavailable
Analysis 2026-08-28 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$22.62M
Beta
0.49
Shares Out
30.74M
P/E (TTM) · Derived
-0.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.61
Rev YoY
-
EPS YoY
+12.7%
Gross Margin
-
Op Margin
-
Net Debt
-$3.32M
Current Ratio
5.58
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data